Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.

Daien, Vincent; Nguyen, Vuong; Essex, Rohan W; Guymer, Robin; Arnold, Jennifer J; Munk, Marion; Ceklic, Lala; Gillies, Mark C; Barthelmes, Daniel (2019). Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project. (In Press). British journal of ophthalmology BMJ Publishing Group 10.1136/bjophthalmol-2019-315055

[img] Text
bjophthalmol-2019-315055.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (403kB) | Request a copy

BACKGROUND To assess the prevalence and characteristics associated with macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD) treated with vascular endothelial growth factor (VEGF) inhibitors. METHODS This was a retrospective, cross-sectional study of nAMD eyes that commenced anti-VEGF between January 2006 and August 2016. MA (absent/extrafoveal/subfoveal) was graded by treating practitioners based on multimodal imaging from April 2016. The prevalence of MA over time and risk factors of MA were assessed. RESULTS The prevalence of MA in a cohort of 1689 eyes was 9.9% (22/222) in eyes within 1 year of starting treatment, 41.5% (71/171) after 5 years and 48.4% (30/62) after 9 years of treatment. Risk factors for subfoveal MA included the proportion of visits at which the lesion was graded as inactive ((adjusted OR (AOR) 3.72 for the highest vs lowest the quartile of frequency of inactive gradings (95% CI 2.33 to 6.07)), age (AOR 1.05 per year (95% CI 1.02 to 1.07)), baseline visual acuity (AOR 3.9 for ≤35 letters vs ≥70 letters (95% CI 2.4 to 6.4)) and the number of injections received (AOR 1.20 every 10 injections (95% CI 1.08 to 1.33)). Similar associations were observed with extrafoveal MA. CONCLUSIONS The risk of MA appeared to drop in eyes that had not developed it within 5 years. Low choroidal neovascularisation activity was by far the strongest predictor. We could not determine whether the increased prevalence of MA with time was due to anti-VEGF treatment or the natural history of the condition.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Munk, Marion

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0007-1161

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Marion Munk

Date Deposited:

14 Jan 2020 09:36

Last Modified:

16 Jan 2020 05:16

Publisher DOI:

10.1136/bjophthalmol-2019-315055

PubMed ID:

31843790

Uncontrolled Keywords:

neovascularisation retina vision

BORIS DOI:

10.7892/boris.137252

URI:

https://boris.unibe.ch/id/eprint/137252

Actions (login required)

Edit item Edit item
Provide Feedback